STOCK TITAN

[8-K] Plumas Bancorp Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

On 17 July 2025, Aptevo Therapeutics (APVO) filed a Form 4 reporting that SoYoung Kwon, SVP & General Counsel, converted 3 restricted stock units (RSUs) into an equal number of common shares (transaction code M). The RSUs carried a $0 exercise price and were part of an 8,550-unit grant (11 units post-reverse-split) awarded on 17 July 2024.

After the conversion, Kwon directly owns 4 common shares and retains 8 unvested RSUs, which are scheduled to vest in two additional annual installments through 17 July 2027. No open-market purchase or sale occurred, and the filing reflects an immaterial change in insider ownership.

Il 17 luglio 2025, Aptevo Therapeutics (APVO) ha presentato un Modulo 4 segnalando che SoYoung Kwon, SVP e Consigliere Generale, ha convertito 3 unità di azioni ristrette (RSU) in un pari numero di azioni ordinarie (codice transazione M). Le RSU avevano un prezzo di esercizio di $0 e facevano parte di una concessione di 8.550 unità (11 unità dopo il raggruppamento azionario) assegnata il 17 luglio 2024.

Dopo la conversione, Kwon possiede direttamente 4 azioni ordinarie e mantiene 8 RSU non maturate, che sono programmate per maturare in due ulteriori tranche annuali fino al 17 luglio 2027. Non si è verificato alcun acquisto o vendita sul mercato aperto e la comunicazione riflette una variazione irrilevante nella proprietà interna.

El 17 de julio de 2025, Aptevo Therapeutics (APVO) presentó un Formulario 4 informando que SoYoung Kwon, SVP y Asesor General, convirtió 3 unidades restringidas de acciones (RSU) en un número igual de acciones comunes (código de transacción M). Las RSU tenían un precio de ejercicio de $0 y formaban parte de una concesión de 8,550 unidades (11 unidades tras la división inversa) otorgada el 17 de julio de 2024.

Tras la conversión, Kwon posee directamente 4 acciones comunes y conserva 8 RSU no adquiridas, que están programadas para adquirirse en dos cuotas anuales adicionales hasta el 17 de julio de 2027. No se realizó ninguna compra o venta en el mercado abierto y la presentación refleja un cambio insignificante en la propiedad interna.

2025년 7월 17일, Aptevo Therapeutics(APVO)는 SoYoung Kwon 부사장 겸 총괄 법무책임자가 3개의 제한 주식 단위(RSU)를 동일 수의 보통주로 전환했다고 Form 4를 제출했습니다(거래 코드 M). 해당 RSU는 행사가격 $0이며, 2024년 7월 17일에 부여된 8,550단위(역병합 후 11단위)의 일부였습니다.

전환 후 Kwon은 직접 4주의 보통주를 보유하고 있으며, 8개의 미확정 RSU를 보유 중입니다. 이 RSU는 2027년 7월 17일까지 두 차례에 걸쳐 추가로 연간 분할하여 확정될 예정입니다. 공개 시장에서의 매매는 없었으며, 이번 제출은 내부자 소유권에 미미한 변동을 반영합니다.

Le 17 juillet 2025, Aptevo Therapeutics (APVO) a déposé un formulaire 4 indiquant que SoYoung Kwon, SVP et conseiller juridique général, a converti 3 unités d'actions restreintes (RSU) en un nombre égal d'actions ordinaires (code transaction M). Les RSU avaient un prix d'exercice de 0 $ et faisaient partie d'une attribution de 8 550 unités (11 unités après regroupement d'actions) accordée le 17 juillet 2024.

Après la conversion, Kwon détient directement 4 actions ordinaires et conserve 8 RSU non acquises, qui doivent être acquises en deux versements annuels supplémentaires jusqu'au 17 juillet 2027. Aucune transaction sur le marché ouvert n'a eu lieu, et le dépôt reflète un changement négligeable dans la détention d'initiés.

Am 17. Juli 2025 reichte Aptevo Therapeutics (APVO) ein Formular 4 ein, in dem berichtet wurde, dass SoYoung Kwon, SVP und General Counsel, 3 Restricted Stock Units (RSUs) in eine gleiche Anzahl von Stammaktien umgewandelt hat (Transaktionscode M). Die RSUs hatten einen Ausübungspreis von 0 $ und waren Teil eines 8.550-Einheiten-Zuschusses (11 Einheiten nach Reverse-Split), der am 17. Juli 2024 gewährt wurde.

Nach der Umwandlung besitzt Kwon direkt 4 Stammaktien und behält 8 nicht erworbene RSUs, die in zwei weiteren jährlichen Raten bis zum 17. Juli 2027 fällig werden. Es fanden keine Käufe oder Verkäufe am offenen Markt statt, und die Meldung spiegelt eine unwesentliche Änderung des Insiderbesitzes wider.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Minor insider RSU vesting; negligible ownership change, low market impact.

The conversion of 3 RSUs into common shares marginally increases Kwon’s direct stake to four shares. Given Aptevo’s float, this is economically insignificant and provides little insight into management’s sentiment or near-term fundamentals. No cash outlay, sale, or option exercise price is involved, so dilution effects are de minimis. I view the disclosure as routine administrative reporting rather than a signal.

TL;DR: Routine Form 4 fulfills Section 16 obligation; governance impact neutral.

The filing demonstrates compliance with insider-trading disclosure rules. The tiny share count—post-reverse-split—and the absence of open-market activity mean alignment incentives are unchanged. Investors should not infer strategic intent from this vesting event. Impact on governance metrics (e.g., insider ownership percentage) is effectively nil.

Il 17 luglio 2025, Aptevo Therapeutics (APVO) ha presentato un Modulo 4 segnalando che SoYoung Kwon, SVP e Consigliere Generale, ha convertito 3 unità di azioni ristrette (RSU) in un pari numero di azioni ordinarie (codice transazione M). Le RSU avevano un prezzo di esercizio di $0 e facevano parte di una concessione di 8.550 unità (11 unità dopo il raggruppamento azionario) assegnata il 17 luglio 2024.

Dopo la conversione, Kwon possiede direttamente 4 azioni ordinarie e mantiene 8 RSU non maturate, che sono programmate per maturare in due ulteriori tranche annuali fino al 17 luglio 2027. Non si è verificato alcun acquisto o vendita sul mercato aperto e la comunicazione riflette una variazione irrilevante nella proprietà interna.

El 17 de julio de 2025, Aptevo Therapeutics (APVO) presentó un Formulario 4 informando que SoYoung Kwon, SVP y Asesor General, convirtió 3 unidades restringidas de acciones (RSU) en un número igual de acciones comunes (código de transacción M). Las RSU tenían un precio de ejercicio de $0 y formaban parte de una concesión de 8,550 unidades (11 unidades tras la división inversa) otorgada el 17 de julio de 2024.

Tras la conversión, Kwon posee directamente 4 acciones comunes y conserva 8 RSU no adquiridas, que están programadas para adquirirse en dos cuotas anuales adicionales hasta el 17 de julio de 2027. No se realizó ninguna compra o venta en el mercado abierto y la presentación refleja un cambio insignificante en la propiedad interna.

2025년 7월 17일, Aptevo Therapeutics(APVO)는 SoYoung Kwon 부사장 겸 총괄 법무책임자가 3개의 제한 주식 단위(RSU)를 동일 수의 보통주로 전환했다고 Form 4를 제출했습니다(거래 코드 M). 해당 RSU는 행사가격 $0이며, 2024년 7월 17일에 부여된 8,550단위(역병합 후 11단위)의 일부였습니다.

전환 후 Kwon은 직접 4주의 보통주를 보유하고 있으며, 8개의 미확정 RSU를 보유 중입니다. 이 RSU는 2027년 7월 17일까지 두 차례에 걸쳐 추가로 연간 분할하여 확정될 예정입니다. 공개 시장에서의 매매는 없었으며, 이번 제출은 내부자 소유권에 미미한 변동을 반영합니다.

Le 17 juillet 2025, Aptevo Therapeutics (APVO) a déposé un formulaire 4 indiquant que SoYoung Kwon, SVP et conseiller juridique général, a converti 3 unités d'actions restreintes (RSU) en un nombre égal d'actions ordinaires (code transaction M). Les RSU avaient un prix d'exercice de 0 $ et faisaient partie d'une attribution de 8 550 unités (11 unités après regroupement d'actions) accordée le 17 juillet 2024.

Après la conversion, Kwon détient directement 4 actions ordinaires et conserve 8 RSU non acquises, qui doivent être acquises en deux versements annuels supplémentaires jusqu'au 17 juillet 2027. Aucune transaction sur le marché ouvert n'a eu lieu, et le dépôt reflète un changement négligeable dans la détention d'initiés.

Am 17. Juli 2025 reichte Aptevo Therapeutics (APVO) ein Formular 4 ein, in dem berichtet wurde, dass SoYoung Kwon, SVP und General Counsel, 3 Restricted Stock Units (RSUs) in eine gleiche Anzahl von Stammaktien umgewandelt hat (Transaktionscode M). Die RSUs hatten einen Ausübungspreis von 0 $ und waren Teil eines 8.550-Einheiten-Zuschusses (11 Einheiten nach Reverse-Split), der am 17. Juli 2024 gewährt wurde.

Nach der Umwandlung besitzt Kwon direkt 4 Stammaktien und behält 8 nicht erworbene RSUs, die in zwei weiteren jährlichen Raten bis zum 17. Juli 2027 fällig werden. Es fanden keine Käufe oder Verkäufe am offenen Markt statt, und die Meldung spiegelt eine unwesentliche Änderung des Insiderbesitzes wider.

false 0001168455 0001168455 2025-07-21 2025-07-21
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 21, 2025
 
PLUMAS BANCORP

(Exact name of registrant as specified in its charter)
 
California   000-49883   75-2987096
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)
 
5525 Kietzke Lane, Suite 100, Reno, Nevada   89511
(Address of principal executive offices)   (Zip Code)
 
Registrant’s telephone number, including area code: (775) 786-0907
 
Not Applicable

(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging Growth Company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
PLBC
NASDAQ Capital Market
 
 
 

 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
(c) On July 21, 2025, Jack Prescott was appointed as Executive Vice President and Chief Banking Officer (“CBO”) of Plumas Bank, the sole subsidiary of Plumas Bancorp.
 
Mr. Prescott served as the Senior Vice President and Commercial Lending Manager at Plumas Bank for 2 years. He brings more than 35 years of experience in lending and leadership. Mr. Prescott earned a bachelor’s degree in business and agricultural economics from the University of Nevada, Reno.
 
Mr. Prescott does not have any family relationship with any of the Company’s directors or executive officers or any persons nominated or chosen by the Company to be a director or an executive officer. He has no direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K or Item 5.02(d) of Form 8-K.
 
Item 9.01. Financial Statements and Exhibits
 
(d) Exhibits
 
Exhibit No.
Description         
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
July 21, 2025  PLUMAS BANCORP
  By: /s/ Richard L. Belstock
    Name: Richard L. Belstock
    Title: Chief Financial Officer
 
 

FAQ

How many APVO shares did SoYoung Kwon acquire on 17-Jul-2025?

The Form 4 shows the conversion of 3 RSUs into 3 common shares.

What does transaction code "M" mean in this APVO Form 4?

Code M indicates an exercise or conversion of a derivative security—in this case, RSUs—into common stock.

What is Kwon’s total APVO share ownership after the transaction?

Following the conversion, Kwon directly owns 4 APVO common shares.

How many RSUs remain unvested for SoYoung Kwon?

Kwon retains 8 unvested RSUs from the original 11-unit (post-split) grant.

Did the RSU conversion involve any cash payment?

No. The RSUs convert on a 1-for-1 basis at a $0 exercise price; no cash changed hands.
Plumas

NASDAQ:PLBC

PLBC Rankings

PLBC Latest News

PLBC Latest SEC Filings

PLBC Stock Data

322.68M
6.22M
11.87%
47.42%
0.98%
Banks - Regional
Short-term Business Credit Institutions
Link
United States
RENO